Many multiple myeloma patients are afflicted by tingling and pain in the hands, arms, feet, and legs (known as peripheral neuropathy). Treatments for myeloma can make this neuropathy worse. Dr. Paul Richardson of the Dana-Farber Cancer Institute discussed the prevention and management of peripheral neuropathy (PN) during an education session on June 7 at the annual American Society of Clinical Oncology (ASCO) meeting.
Dr. Richardson explained that myeloma, itself, causes nerve damage that leads to the pain and tingling. Up …
Read the full story »
Multiple myeloma patients are at an increased risk of developing deep vein blood clots, and several myeloma treatments further increase the risk. However, blood clots can often be prevented with the use of blood thinners, according to Dr. Todd Zimmerman of the University of Chicago during a myeloma education session on June 7 at the annual American Society of Clinical Oncology (ASCO) meeting.
Dr. Zimmerman reported that there is a nine-fold increase of deep vein thrombosis (a blood clot in …
Read the full story »
Having multiple myeloma isn't simple – It's hard! Not only do you have cancer, but you also have a dizzying array of treatment options available to you. Additionally, it doesn’t just affect your health–it can affect just about all aspects of your life.
First, you and your caregiver need to decide where to go for treatment. Do you travel across state lines to a large, regional or national cancer center that specializes in treating myeloma? Or do …
Read the full story »
Yesterday was the fourth day of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Although today is the final day of the meeting, the multiple myeloma-related sessions concluded yesterday.
The day began with a meeting-wide session to review the highlights of the previous day across all cancer types. There were six presentations, and despite all of the types of cancers being discussed at the meeting, an entire presentation was devoted to myeloma.
Dr. Jean-Luc Harousseau from the …
Read the full story »
The third day of the American Society of Clinical Oncology (ASCO) 2010 annual meeting in Chicago was tailor-made for morning people interested in multiple myeloma. The key myeloma-related activity on Sunday, June 6 was a morning abstract session starting at 9:30 a.m. Nine abstracts were presented and discussed over the course of three hours.
The first two presentations dealt with Velcade (bortezomib)-related research.
Dr. Antonio Palumbo of the University of Turin presented the results of the first study. It compared two regimens for …
Read the full story »
Yesterday -- Saturday, June 5 -- was the second day of the American Society of Clinical Oncology (ASCO) 2010 annual meeting in Chicago. It was a busy day in terms of research posters and presentations related to multiple myeloma. As a result, there is a lot of ground to cover in this update.
Almost 40 myeloma-related posters were up for meeting attendees to view during the daytime poster session on "lymphoma and plasma cell disorders." Among those 40-or-so posters, six concerned research done by …
Read the full story »
Friday, June 4, was the first day of this year's American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Most of the big multiple myeloma news of the day came out of a poster session in the afternoon.
At "poster sessions," researchers present a poster-sized summary of their research in a small, 2 meter by 1 meter cubicle. Researchers and physicians mill about, taking pictures of the posters with their cell phone cameras or taking notes. Sometimes one or more …
Read the full story »

